Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients
Observational studyDogs
- Design
- Observational study
- Subjects
- 26 dogs with B-cell lymphoma, 14 with T-cell lymphoma, 12 healthy control dogs
- Dose used in the study
- No PEA given. Serum levels of the dog's own PEA and other endocannabinoids were measured
- Duration
- Not stated in the abstract
- What was measured
- Serum 2-AG, oleoylethanolamide, anandamide and PEA by mass spectrometry; progression-free interval and survival.
What the authors reported
PEA, oleoylethanolamide and anandamide were higher in dogs with lymphoma than in healthy dogs. Higher PEA was associated with a shorter progression-free interval (hazard ratio 1.8, p = 0.04). Total AG, unlike the other markers, was higher in healthy dogs than in dogs with lymphoma (p = 0.049).
Limits of this study
A study of the body's own PEA as a disease marker, not of supplementation. 52 dogs in total. The association with faster progression is a correlation in a small group and says nothing about giving PEA. Authors declare no conflicts.
Source
PubMed 35242839 · doi:10.3389/fvets.2022.828095
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.